Institut de Neuropsiquiatria i Addiccions (INAD), Hospital del Mar, Parc de Salut Mar, 08003 Barcelona, Spain.
Gen Hosp Psychiatry. 2011 Jul-Aug;33(4):363-70. doi: 10.1016/j.genhosppsych.2011.03.004. Epub 2011 Apr 27.
The objective of the study was to assess whether joint hypermobility syndrome (JHS) is a risk factor for developing anxiety disorders using a 15-year prospective cohort study.
The initial cohort recruited 158 subjects aged 16 to 20 years from the general population in a Spanish rural town. The cohort was studied at baseline and at a 15-year follow-up. Joint hypermobility syndrome was assessed using Beighton's criteria, and the psychiatric disorders were assessed using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Disorders. Subjects with anxiety disorders at baseline were excluded from the follow-up.
Joint hypermobility syndrome at baseline was found in 29 of 158 subjects (21.1%). Cumulative incidence of panic/agoraphobia disorder at follow-up, as main diagnosis, was significantly higher for the JHS group (41.4%) than for the control group (1.9%), with a relative risk of 22.3 [95% confidence interval (CI) 4.6-108.7, P<.0001] (Number Needed to Treat [NNT] 3, 95% CI 2.9-2.3). Incidence of social phobia and simple phobia was also significantly higher for the JHS group [relative risk (RR)=6.52, 95% CI 1.7-24.2, P<.001 and RR=3.31, 95% CI 1.1-9.6, P=.02, respectively]. Moreover, anxiolytic drug use was nearly fourfold higher among JHS compared to non-JHS subjects.
Joint hypermobility syndrome was associated with higher risk of developing anxiety disorders. If replicated, these findings may give enhanced value to JHS assessment in clinical and general population studies.
本研究旨在通过一项为期 15 年的前瞻性队列研究,评估关节过度活动综合征(JHS)是否为焦虑障碍发展的危险因素。
初始队列从西班牙一个农村城镇的一般人群中招募了 158 名年龄在 16 至 20 岁的受试者。该队列在基线和 15 年随访时进行了研究。使用 Beighton 标准评估 JHS,使用《精神障碍诊断与统计手册》第四版的结构临床访谈评估精神障碍。排除基线时患有焦虑障碍的受试者参加随访。
基线时有 29 名 158 名受试者(21.1%)患有 JHS。作为主要诊断,随访时惊恐/广场恐怖障碍的累积发生率在 JHS 组(41.4%)明显高于对照组(1.9%),相对风险为 22.3[95%置信区间(CI)4.6-108.7,P<.0001](需要治疗的人数[NNT]为 3,95%CI 2.9-2.3)。JHS 组的社交恐惧症和单纯恐惧症的发生率也明显更高[相对风险(RR)分别为 6.52,95%CI 1.7-24.2,P<.001 和 3.31,95%CI 1.1-9.6,P=.02]。此外,JHS 组的抗焦虑药物使用几乎是非 JHS 组的四倍。
JHS 与焦虑障碍发生风险增加相关。如果得到复制,这些发现可能会增加 JHS 在临床和一般人群研究中的评估价值。